Prof. Dr. İBRAHİM CELALETTİN HAZNEDAROĞLU

Yayın Ağı

Makaleler 270

1. Hepatic Metabolic Dysregulation as a Potential Amplifier of Leukemogenesis Following mRNA Vaccination: A Novel Mechanistic Hypothesis

Erdogdu B., KAPLAN O., ÇELEBİER M., MALKAN Ü. Y., HAZNEDAROĞLU İ. C.

MEDICINA-LITHUANIA , cilt.61, sa.9, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

2. Anemia in the patients with acute myeloid leukemia revisited: Prognostic importance of anemia on treatment-naïve patients

Çınar O. E., Malkan U. Y., Aladag E., Demiroglu H., Büyükaşık Y., Göker H., et al.

Acta Medica , cilt.56, sa.2, ss.116-121, 2025 (TRDizin)

3. Metabolomic Profiling of Leukemic Hematopoiesis: Effects of BNT162b2 mRNA COVID-19 Vaccine Administration

Erdogdu B., KAPLAN O., Fidan B. B., ÇELEBİER M., MALKAN Ü. Y., HAZNEDAROĞLU İ. C.

CURRENT MOLECULAR MEDICINE , 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

4. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study

Gupta V., Tomuleasa C., Lampon G. I. B., Hou H., Helbig G., Vachhani P., et al.

BLOOD ADVANCES , sa.5, ss.1105-1116, 2025 (SCI-Expanded, Scopus)

5. **Differential proinflammatory responses of colon epithelial cells to SARS-CoV-2 spike protein and Pseudomonas aeruginosa lipopolysaccharide**

YILMAZ A., Turk S., MALKAN Ü. Y., HAZNEDAROĞLU İ. C., Ucar G., ÖZGÜVEN Ş. V., et al.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI , cilt.49, ss.774-783, 2024 (SCI-Expanded, Scopus)

6. Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia Kronik Miyeloid Lösemi Tanılı Hastada Nilotinib ile İlişkili Çoklu Sessiz Arteriyel Darlık

Tokatlı M., Ismayilov R., ÇINAR O. E., HAZNEDAROĞLU İ. C.

Turkish Journal of Hematology , cilt.41, sa.1, ss.59-60, 2024 (SCI-Expanded, Scopus, TRDizin)

7. The Potential Role of CAL2 and EZH2 Immunohistochemical Stainings as Diagnostic and Prognostic Surrogate Markers in Classical BCR/ABL1-negative Myeloproliferative Neoplasms

ÖZOĞUL E., Ozgeyik M. O., AYHAN E. A., MALKAN Ü. Y., HAZNEDAROĞLU İ. C., ÜNER A.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.33, sa.4, ss.248-257, 2023 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

8. Immunogenomic approach to the clinical management of COVID-19 syndrome

TÜRK S., HAZNEDAROĞLU İ. C., TÜRK C., malkan Ü. Y.

Eskisehir Medical Journal , cilt.4, ss.266-279, 2023 (Hakemli Dergi)

9. Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders

Malkan U. Y., Haznedaroglu I. C.

The European Research Journal , cilt.9, sa.5, ss.1271-1276, 2023 (TRDizin)

10. Enterotoxins A and B produced by Staphylococcus aureus increase cell proliferation, invasion and cytarabine resistance in acute myeloid leukemia cell lines.

TÜRK S., Yanpar H., Baesmat A. S., Canli S., ÇINAR O. E., MALKAN Ü. Y., et al.

Heliyon , cilt.9, sa.9, 2023 (SCI-Expanded, Scopus)

11. The effects of Ankaferd hemostat on preventing oral mucositis in colorectal cancer patients receiving chemotherapy

Karacan Y., YILDIZ H., EVRENSEL T., HAZNEDAROĞLU İ. C.

Supportive Care in Cancer , cilt.31, sa.7, 2023 (SCI-Expanded, Scopus)

12. Exploring the distribution and prognostic effect of the ABO blood types of COVID-19 patients during delta and omicron waves: A case control study

GÖKER H., ÇINAR O. E., ISMAYILOV R., Özdemir E., MALKAN Ü. Y., ALADAĞ E., et al.

Acta Medica , cilt.54, sa.2, ss.97-102, 2023 (Hakemli Dergi)

13. Pathobiological alterations affecting the distinct clinical courses of pediatric versus adult COVID-19 syndrome

ŞENEL E., TÜRK S., MALKAN Ü. Y., Peker M. Ç., TÜRK C., GÜNER H. R., et al.

Turkish Journal of Medical Sciences , cilt.53, sa.5, ss.1194-1204, 2023 (SCI-Expanded, Scopus, TRDizin)

14. A single-center experience of haploidentical stem cell transplantation in hematological malignancies

MALKAN Ü. Y., GÖKER H., DEMİROĞLU H., Tekin F., Akdemir B., ALADAĞ KARAKULAK E., et al.

Turkish Journal of Medical Sciences , cilt.53, sa.1, ss.352-359, 2023 (SCI-Expanded, Scopus, TRDizin)

15. Harbinger of Trouble; Fingerprints in the Pre-Senile Stage of NK Cell’s Dysfunction

TÜRK S., Baesmat A. S., YILMAZ A., MALKAN Ü. Y., TÜRK C., HAZNEDAROĞLU İ. C., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.33, sa.2, ss.66-74, 2023 (SCI-Expanded, Scopus, TRDizin)

16. Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study

Canbaz H., İdiz U. O., Cankar Dal H., Kaçıroğlu F., Taş S., Çubukçu H. C., et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.39, sa.4, ss.222-229, 2022 (SCI-Expanded, Scopus, TRDizin)

17. Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874

ÇINAR O. E., Erdogdu B., KARADENİZ M., ÜNAL S., MALKAN Ü. Y., GÖKER H., et al.

MEDICINA-LITHUANIA , cilt.58, sa.11, 2022 (SCI-Expanded, Scopus)

18. NK-cell dysfunction of acute myeloid leukemia in relation to the renin-angiotensin system and neurotransmitter genes

TÜRK S., Baesmat A. S., YILMAZ A., TÜRK C., MALKAN Ü. Y., UÇAR G., et al.

OPEN MEDICINE , cilt.17, sa.1, ss.1495-1506, 2022 (SCI-Expanded, Scopus)

19. Review on Characteristics and Analytical Methods of Rivaroxaban

REÇBER T., HAZNEDAROĞLU İ. C., ÇELEBİER M.

CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY , cilt.52, sa.4, ss.865-877, 2022 (SCI-Expanded, Scopus)

20. Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation

KARATAŞ A., GÖKER H., DEMİROĞLU H., MALKAN Ü. Y., Velet M., ÇINAR O. E., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.2, ss.413-419, 2022 (SCI-Expanded, Scopus, TRDizin)

21. Bone Marrow Origin of Coronary Artery Diseases: The Impact of the Local Renin-Angiotensin System

KARAKULAK U. N., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C.

ACTA CARDIOLOGICA SINICA , cilt.38, sa.1, ss.13-20, 2022 (SCI-Expanded, Scopus)

22. Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine

Erdogdu B., ÇINAR O. E., Malkan Ü. Y., AKSU S., DEMİROĞLU H., BÜYÜKAŞIK Y., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.32, sa.1, ss.65-67, 2022 (SCI-Expanded, Scopus, TRDizin)

23. Covid-19 Related Fatality and Risk Factors in Multiple Myeloma: A Multicenter Cohort Study

KARADENİZ M., GÖKER H., Aydin O., Turgut M., MALKAN Ü. Y., Sener E., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.32, sa.4, ss.209-213, 2022 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

24. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia

İLHAN O., Narli Ozdemir Z., DALVA K., ARSLAN A., Okay Ozgeyik M., Ipek S., et al.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY , cilt.43, sa.5, ss.1110-1116, 2021 (SCI-Expanded, Scopus)

25. Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemia

ALADAĞ KARAKULAK E., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.60, sa.2, 2021 (SCI-Expanded, Scopus)

26. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors

KARAKULAK U. N., ALADAĞ KARAKULAK E., HEKİMSOY V., ŞAHİNER M. L., KAYA E. B., ÖZER N., et al.

CARDIOVASCULAR TOXICOLOGY , cilt.21, sa.3, ss.216-223, 2021 (SCI-Expanded, Scopus)

27. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Munster Chemotherapy in Adult Acute Lymphoblastic Leukemia

ALADAĞ KARAKULAK E., Aktimur S. H., Aydin O., DEMİROĞLU H., BÜYÜKAŞIK Y., AKSU S., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.21, sa.3, ss.147-153, 2021 (SCI-Expanded, Scopus)

28. Current community transmission and future perspectives on the COVID-19 process

TÜRK S., Turk C., Malkan Ü. Y., Temirci E. S., Peker M. C., HAZNEDAROĞLU İ. C.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.51, sa.3, ss.1001-1011, 2021 (SCI-Expanded, Scopus, TRDizin)

29. Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?

ÇELEBİER M., HAZNEDAROĞLU İ. C.

COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING , cilt.24, sa.4, ss.587-590, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

30. Interferon-Gene Family Alterations Following the SARS-Cov Infection in Association with Iron Metabolism and Lymphoid Biology

Malkan Ü. Y., TÜRK S., Turk C., Temirci E. S., Koker I., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.31, sa.2, ss.67-78, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

31. Protein Kinases in Hematological Disorders

OKAY M., HAZNEDAROĞLU İ. C.

PROTEIN KINASE-MEDIATED DECISIONS BETWEEN LIFE AND DEATH , cilt.1275, ss.383-393, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

32. Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation

Ciftciler R., GÖKER H., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.1, ss.33-40, 2021 (SCI-Expanded, Scopus, TRDizin)

33. Exposure of Hepatocellular Carcinoma Cells to Ankaferd Blood Stopper (R) Alters Cell Death Signaling Networks Confirmed by Oncoproteomic and Genomic Profiling Studies

NENNİ M., ÖNCÜL S., ERCAN A., ÇELEBİER M., SÜSLÜ İ., HAZNEDAROĞLU İ. C.

CURRENT TRADITIONAL MEDICINE , cilt.7, sa.2, ss.223-235, 2021 (ESCI, Scopus)

34. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey

SOYER N., ALİ R., Turgut M., HAZNEDAROĞLU İ. C., Yilmaz F., AYDOĞDU İ., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.51, sa.3, ss.1033-1042, 2021 (SCI-Expanded, Scopus, TRDizin)

35. Covid-19 scientific publications from Turkey

Ciftciler R., HAZNEDAROĞLU İ. C., TUFAN A., ÖZTÜRK M. A.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.51, sa.3, ss.877-889, 2021 (SCI-Expanded, Scopus, TRDizin)

36. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

BEYAZIT F., BEYAZIT Y., Tanoglu A., HAZNEDAROĞLU İ. C.

MEDICAL HYPOTHESES , cilt.143, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. Pathobiological Interactions of Local Bone Marrow Renin-Angiotensin System and Central Nervous System in Systemic Arterial Hypertension

Ciftciler R., HAZNEDAROĞLU İ. C.

FRONTIERS IN ENDOCRINOLOGY , cilt.11, 2020 (SCI-Expanded, Scopus)

38. Spontaneous subepithelial hemorrhage of renal pelvis and ureter (Antopol-Goldman lesion) in hemophilia A patient with inhibitor Case report and review of the literature

ŞAHİN T. K., ALADAĞ KARAKULAK E., Setterzade E., SAİN GÜVEN G., HAZNEDAROĞLU İ. C., AKSU S.

MEDICINE , cilt.99, sa.26, 2020 (SCI-Expanded, Scopus)

39. In vitro analysis of the renin-angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus

Turk C., TÜRK S., Temirci E. S., Malkan Ü. Y., HAZNEDAROĞLU İ. C.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM , cilt.21, sa.2, 2020 (SCI-Expanded, Scopus)

40. Richter's transformation in patients with chronic lymphocytic leukemia: a cohort study about risk factors

OKAY M., GÜNEŞ G., Malkan Ü. Y., Heziyev T., GÖKER H., HAZNEDAROĞLU İ. C., et al.

LEUKEMIA & LYMPHOMA , cilt.61, ss.50-52, 2020 (SCI-Expanded, Scopus)

41. Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)

Ciftciler R., Ciftciler A. E., Malkan Ü. Y., HAZNEDAROĞLU İ. C.

SAGE OPEN MEDICINE , cilt.8, 2020 (ESCI, Scopus)

42. COVID-19, Renin-Angiotensin System, and Hematopoiesis

Ciftciler R., HAZNEDAROĞLU İ. C.

TURKISH JOURNAL OF HEMATOLOGY , cilt.37, sa.3, ss.207-208, 2020 (SCI-Expanded, Scopus, TRDizin)

43. Antiinfective and wound-healing pleiotropic actions of Ankaferd hemostat

HAZNEDAROĞLU İ. C., ÇELEBİER M.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.50, sa.5, ss.1434-1435, 2020 (SCI-Expanded, Scopus, TRDizin)

44. The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia

Ciftciler R., HAZNEDAROĞLU İ. C., SAYINALP N., Ozcebe O., AKSU S., DEMİROĞLU H., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.37, sa.2, ss.116-120, 2020 (SCI-Expanded, Scopus, TRDizin)

45. Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis

Ciftciler R., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.37, sa.4, ss.256-262, 2020 (SCI-Expanded, Scopus, TRDizin)

46. Ankaferd Hemostat Affects Etoposide Resistance of the Malignant Melanoma Cells

Ghasemi M., OKAY M., Malkan Ü. Y., TÜRK S., Jabbar J., Hocaoglu H., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.30, sa.1, ss.43-53, 2020 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

47. The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapy

Ciftciler R., HAZNEDAROĞLU İ. C., Ozcebe O., AKSU S., SAYINALP N., GÖKER H., et al.

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , cilt.42, sa.1, ss.17-21, 2020 (SCI-Expanded, Scopus)

48. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

HAZNEDAROĞLU İ. C., KUZU I., İLHAN O.

TURKISH JOURNAL OF HEMATOLOGY , cilt.37, sa.1, ss.42-47, 2020 (SCI-Expanded, Scopus, TRDizin)

49. Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients

Ciftciler R., GÖKER H., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., et al.

HEMATOLOGY REPORTS , cilt.12, sa.1, 2020 (ESCI, Scopus)

50. Local Bone Marrow Renin-Angiotensin System and COVID-19

Ciftciler R., Ciftciler A. E., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.30, sa.2, ss.113-120, 2020 (SCI-Expanded, Scopus, TRDizin)

51. Effects of Smoking on Hematological Parameters and Ferritin Levels

Ciftciler R., Guven A., HAZNEDAROĞLU İ. C., AKSU S.

HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI , cilt.57, sa.4, ss.372-376, 2019 (ESCI, Scopus, TRDizin)

52. Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia

Ciftciler R., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., Ozcebe O., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.19, sa.11, ss.729-734, 2019 (SCI-Expanded, Scopus)

53. A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia

Ciftciler R., Saglam E. A., Inanc A., Ozcebe O., HAZNEDAROĞLU İ. C.

CANCER GENETICS , cilt.237, ss.78-81, 2019 (SCI-Expanded, Scopus)

54. Ghosal hematodiaphyseal dysplasia with autoimmune anemia in two adult siblings

Ciftciler R., BÜYÜKAŞIK Y., Saglam E. A., HAZNEDAROĞLU İ. C.

TRANSFUSION AND APHERESIS SCIENCE , cilt.58, sa.4, ss.449-452, 2019 (SCI-Expanded, Scopus)

55. CYTOGENETIC ANOMALIES IN MULTIPLE MYELOMA PATIENTS: A SINGLE CENTER STUDY

BOZKURT S., BÜYÜKAŞIK Y., DEMİROĞLU H., ALADAĞ KARAKULAK E., OKAY M., KARATAŞ A., et al.

Genetics and Application , cilt.3, sa.1, ss.51-56, 2019 (Hakemli Dergi)

56. The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia

Ghasemi M., OKAY M., TÜRK S., Naeemaee R., Guver E., Malkan Ü. Y., et al.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM , cilt.20, sa.2, 2019 (SCI-Expanded, Scopus)

57. The Impact of AT1R Inhibition via Losartan on the Anti-Leukemic Effects of Doxorubicin in Acute Myeloid Leukemia.

GHASEMİ m., OKAY M., TÜRK S., HAZNEDAROĞLU İ. C., AKSU S., SAYINALP N., et al.

Journal Of The Renin-Angiotensin-Aldosterone System , 2019 (SCI-Expanded, Scopus)

58. The impact of JAK/STAT inhibitor ruxolutinib on the genesis of lymphoproliferative diseases

TÜRK TÜRK S., HAZNEDAROĞLU İ. C., TÜRK C.

Turkish Journal Of Medical Sciences , 2019 (SCI-Expanded, Scopus, TRDizin)

59. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia

Ciftciler R., DEMİROĞLU H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.19, sa.3, ss.177-182, 2019 (SCI-Expanded, Scopus)

60. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma

OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., Malkan Ü. Y., Ciftciler R., ALADAĞ KARAKULAK E., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.49, sa.4, ss.985-992, 2019 (SCI-Expanded, Scopus, TRDizin)

61. Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia

Malkan U. Y., HAZNEDAROĞLU İ. C.

OPEN MEDICINE , cilt.14, sa.1, ss.22-24, 2019 (SCI-Expanded, Scopus)

62. Indications and outcomes of splenectomy for hematological disorders

Ciftciler R., Pasayeva A., AKSU S., Ozcebe O., SAYINALP N., Malkan Ü. Y., et al.

OPEN MEDICINE , cilt.14, sa.1, ss.491-496, 2019 (SCI-Expanded, Scopus)

63. Branch retinal vein occlusion associated with platelet activation

Beyazyildiz E., Citirik M., Simsek M., Beyazyildiz O., HAZNEDAROĞLU İ. C.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.49, sa.1, ss.283-287, 2019 (SCI-Expanded, Scopus, TRDizin)

64. Current perspectives for the treatment of chronic myeloid leukemia

ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.49, sa.1, ss.1-10, 2019 (SCI-Expanded, Scopus, TRDizin)

65. The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases

Turk C., OKAY M., TÜRK S., Temirci E. S., Javad O., AKSU S., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.49, sa.2, ss.661-674, 2019 (SCI-Expanded, Scopus, TRDizin)

66. Fibrosis Development, Leukemic Transformation and Secondary Malignancies Complicating the Clinical Course of Essential Thrombocythemia

Ciftciler R., AKSU S., Malkan Ü. Y., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.29, sa.1, ss.14-21, 2019 (SCI-Expanded, Scopus, TRDizin)

67. Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach

KOÇAK E., ÇELEBİER M., HAZNEDAROĞLU İ. C., ALTINÖZ S.

BIOMED RESEARCH INTERNATIONAL , cilt.2019, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

68. Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance

Ciftciler R., KOLUMAN A., HAZNEDAROĞLU İ. C., Akar N.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.49, sa.1, ss.347-355, 2019 (SCI-Expanded, Scopus, TRDizin)

69. The factors affecting early death in newly diagnosed APL patients

Ciftciler R., HAZNEDAROĞLU İ. C., AKSU S., Ozcebe O., SAYINALP N., Malkan Ü. Y., et al.

OPEN MEDICINE , cilt.14, sa.1, ss.647-652, 2019 (SCI-Expanded, Scopus)

70. Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia

OKAY M., ÇETİK S., HAZNEDAROĞLU İ. C.

TURKISH JOURNAL OF HEMATOLOGY , cilt.36, sa.3, ss.218-219, 2019 (SCI-Expanded, Scopus, TRDizin)

71. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency

ALADAĞ KARAKULAK E., AKSU S., DEMİROĞLU H., SAYINALP N., GÖKER H., HAZNEDAROĞLU İ. C., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.49, sa.5, ss.1560-1563, 2019 (SCI-Expanded, Scopus, TRDizin)

72. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study

Ciftciler R., GÖKER H., DEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.36, sa.2, ss.88-96, 2019 (SCI-Expanded, Scopus, TRDizin)

73. The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine

OKAY M., Ozturk Y., HAZNEDAROĞLU İ. C.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.25, 2019 (SCI-Expanded, Scopus)

74. Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome

ÇİFTÇİLER R., SAĞLAM E. A., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C.

Medical Science and Discovery , cilt.5, sa.12, ss.390-392, 2018 (Hakemli Dergi)

75. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients

CIFTCILER R., DEMİROĞLU H., BÜYÜKAŞIK Y., OKAY M., AKSU S., Sayinalp N., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.57, sa.6, ss.752-755, 2018 (SCI-Expanded, Scopus)

76. On Being a "Physician Patient" with His Own Experimental Therapeutic Drug

Ciftciler R., HAZNEDAROĞLU İ. C.

TURKISH JOURNAL OF HEMATOLOGY , cilt.35, sa.4, ss.302-303, 2018 (SCI-Expanded, Scopus, TRDizin)

77. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up

SAYDAM G., HAZNEDAROĞLU İ. C., KAYNAR L., Yavuz A., ALİ R., GÜVENÇ B., et al.

HEMATOLOGY , cilt.23, sa.10, ss.771-777, 2018 (SCI-Expanded, Scopus)

78. Evaluation of Secondary Malignancies in Chronic Lymphocytic Leukemia

DEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.

Journal of Global Oncology , ss.205, 2018 (ESCI)

79. Pediatric Chemotherapeutic Regimen (BFM-95) is Superior for Overall Survival in Adult Acute Lymphoblastic Leukemia

KARCIOĞLU A. M., OKAY M., BÜYÜKAŞIK Y., Malkan Ü. Y., SAYINALP N., DEMİROĞLU H., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.28, sa.4, ss.254-260, 2018 (SCI-Expanded, Scopus, TRDizin)

80. The impact of chemo/immune therapy-related cytopenias on the clinical course of chronic lymphoid leukemia

Malkan Ü. Y., OKAY M., HAZNEDAROĞLU İ. C., GÜNEŞ G., Aslan N. A., ÖZCEBE O. İ., et al.

LEUKEMIA & LYMPHOMA , cilt.58, ss.96, 2017 (SCI-Expanded)

81. Farklı Trombositopeni Sebeplerinin Klinik ve Laboratuvar Bulguları

AKIN S., AKIN Ş., Karaağaç A. T., HAZNEDAROĞLU İ. C.

Journal of Contemporary Medicine , cilt.7, sa.4, ss.316-322, 2017 (Hakemli Dergi)

82. Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission

AYDIN M. S., BOZKURT S., GÜNEŞ G., Malkan Ü. Y., Aslan T., ETGÜL S., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.34, sa.1, ss.103-104, 2017 (SCI-Expanded, Scopus, TRDizin)

83. A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment

Malkan Ü. Y., HAZNEDAROĞLU İ. C.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE , cilt.10, sa.4, ss.7304-7307, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

84. Lipotoxicity-Related Hematological Disorders in Obesity

HAZNEDAROĞLU İ. C., MALKAN Ü. Y.

OBESITY AND LIPOTOXICITY , cilt.960, ss.469-487, 2017 (SCI-Expanded)

85. Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases

Koluman A., Akar N., HAZNEDAROĞLU İ. C.

TURKISH JOURNAL OF HEMATOLOGY , cilt.34, sa.1, ss.93-98, 2017 (SCI-Expanded, Scopus, TRDizin)

86. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms

SOYER N., HAZNEDAROĞLU İ. C., Comert M., Cekdemir D., YILMAZ M., ÜNAL A., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.34, sa.1, ss.27-33, 2017 (SCI-Expanded, Scopus, TRDizin)

87. Ankaferd hemostat induces DNA damage, apoptosis and cytotoxic activity by generating reactive oxygen species in melanoma and normal cell lines

KOÇYİĞİT A., GÜLER E. M., HAZNEDAROĞLU İ. C., Malkan Ü. Y.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE , cilt.10, sa.2, ss.2116-2126, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

88. Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper

ŞİMŞEK C., Selek S., Koca M., HAZNEDAROĞLU İ. C.

SAGE OPEN MEDICINE , cilt.5, 2017 (ESCI, Scopus)

89. Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines

TÜRK TÜRK S., Malkan Ü. Y., Ghasemi M., Hocaoglu H., Mutlu D., Gunes G., et al.

SAGE OPEN MEDICINE , cilt.5, 2017 (ESCI, Scopus)

90. Clinical associations, biological risk factors and outcomes of cerebral venous sinus thrombosis

Gunes H. N., Cokal B. G., Guler S. K., Yoldas T. K., Malkan Ü. Y., Demircan C. S., et al.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH , cilt.44, sa.6, ss.1454-1461, 2016 (SCI-Expanded, Scopus)

91. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

SAYDAM G., HAZNEDAROĞLU İ. C., KAYNAR L., Yavuz A., ALİ R., GÜVENÇ B., et al.

EXPERT OPINION ON PHARMACOTHERAPY , cilt.17, sa.14, ss.1851-1858, 2016 (SCI-Expanded, Scopus)

92. Splenic artery embolization with Ankaferd blood stopper in a sheep model

KOÇ O., Acar K., Ozbek O., Guler I., Saritas K., Erdem T. B., et al.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY , cilt.22, sa.4, ss.354-357, 2016 (SCI-Expanded, Scopus, TRDizin)

93. Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib

Malkan U. Y., GÜNEŞ G., ETGÜL S., Aslan T., Aydin S., HAZNEDAROĞLU İ. C.

ANNALS OF PHARMACOTHERAPY , cilt.50, sa.4, ss.336, 2016 (SCI-Expanded, Scopus)

94. The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice

Malkan Ü. Y., GÜNEŞ G., GÖKER H., HAZNEDAROĞLU İ. C., Acar K., ELİAÇIK E., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.33, sa.4, ss.281-285, 2016 (SCI-Expanded, Scopus, TRDizin)

95. Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case

Malkan Ü. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C.

INTERNATIONAL MEDICAL CASE REPORTS JOURNAL , cilt.9, ss.61-64, 2016 (ESCI, Scopus)

96. Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma

GHASEMİ m., ALPSOY S., TÜRK TÜRK S., MALKAN Ü. Y., ATAKAN Ş., HAZNEDAROĞLU İ. C., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.33, sa.4, ss.286-292, 2016 (SCI-Expanded, Scopus, TRDizin)

97. Peripheral FLT-3 ligand levels as a pathobiological parameter during the clinical course of acute myeloid leukemia

Sahin M., HAZNEDAROĞLU İ. C., Ozbalci D.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.46, sa.6, ss.1889-1893, 2016 (SCI-Expanded, Scopus, TRDizin)

98. A CML case with resistant pleural effusion with tyrosine kinase inhibitor treatment

Malkan Ü. Y., HAZNEDAROĞLU İ. C.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE , cilt.9, sa.7, ss.14884-14887, 2016 (SCI-Expanded, Scopus)

99. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems

BEKTAŞ Ö., ÜNER A., ELİAÇIK E., Uz B., Isik A., ETGÜL S., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.33, sa.2, ss.119-126, 2016 (SCI-Expanded, Scopus, TRDizin)

100. Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids

Koluman A., Akar N., Malkan U. Y., HAZNEDAROĞLU İ. C.

BIOMED RESEARCH INTERNATIONAL , cilt.2016, 2016 (SCI-Expanded, Scopus)

101. A Bing-Neel syndrome case

Malkan Ü. Y., HAZNEDAROĞLU İ. C.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE , cilt.9, sa.11, ss.22660-22663, 2016 (SCI-Expanded, Scopus)

102. Dasatinib-Induced Severe Hemorrhagic Colitis in Chronic Myeloid Leukemia

Kekilli M., Tanoglu A., Cakar M. K., Guney G., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.1, ss.67-68, 2016 (SCI-Expanded, Scopus, TRDizin)

103. The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases

Aktimur S. H., Malkan U. Y., Eyupoglu D. N., HAZNEDAROĞLU İ. C., KELKİTLİ E., Atay H. M., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.3, ss.153-158, 2016 (SCI-Expanded, Scopus, TRDizin)

104. Idelalisib at the Crossroads of B-Cell Lymphoproliferative Disorders

AKSU S., Ayyildiz O., ETGÜL S., GÖKER H., GÜNEŞ G., HAZNEDAROĞLU İ. C., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.1, ss.12-19, 2016 (SCI-Expanded, Scopus, TRDizin)

105. Molecular Management of Chronic Lymphocytic Leukemia: Towards a Chemotherapy-Free Approach

SAYINALP N., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.1, ss.1-11, 2016 (SCI-Expanded, Scopus, TRDizin)

106. The Impact of Iron Overload on Transplant-Related Complications and Prognosis of Acute Leukemias

Malkan U. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., Yayar O., ETGÜL S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.1, ss.54-60, 2016 (SCI-Expanded, Scopus, TRDizin)

107. High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology

BEKTAŞ Ö., ÜNER A., Aydin S. M., ELİAÇIK E., Uz B., Isik A., et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY , cilt.102, sa.2, ss.211-217, 2015 (SCI-Expanded, Scopus)

108. Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia

ELİAÇIK E., Isik A., Aydin C., ÜNER A., AKSU S., SAYINALP N., et al.

HEMATOLOGY , cilt.20, sa.7, ss.392-396, 2015 (SCI-Expanded, Scopus)

109. In Vivo Healing Effects of Ankaferd Blood Stopper on the Residual Pancreatic Tissue in a Swine Model of Distal Pancreatectomy

Karaman K., Bostanci E. B., Celep B., Dincer N., Kurt M., Teke Z., et al.

INDIAN JOURNAL OF SURGERY , cilt.77, sa.3, ss.176-181, 2015 (SCI-Expanded, Scopus)

110. Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib

Malkan Ü. Y., GÜNEŞ G., ETGÜL S., Aslan T., Balaban S., HAZNEDAROĞLU İ. C.

ANNALS OF PHARMACOTHERAPY , cilt.49, sa.6, ss.740-742, 2015 (SCI-Expanded, Scopus)

111. Severe radiation esophagitis successfully treated with Ankaferd hemostat

ÖZTÜRK Ö., KÖKLÜ S., BAŞAR Ö., HAZNEDAROĞLU İ. C.

GASTROINTESTINAL ENDOSCOPY , cilt.81, sa.4, ss.1048-1049, 2015 (SCI-Expanded, Scopus)

112. High iron content of Ankaferd hemostat as a clue for its hemostatic action of red blood cell origin

Akar N., Ardicoglu Y., ÖKTEM Z., ERDURAN N., HAZNEDAROĞLU İ. C.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.26, sa.2, ss.233-234, 2015 (SCI-Expanded, Scopus)

113. The factors affecting early death after the initial therapy of acute myeloid leukemia

Malkan Ü. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., ETGÜL S., Aslan T., et al.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE , cilt.8, sa.12, ss.22564-22569, 2015 (SCI-Expanded, Scopus)

114. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms

ELİAÇIK E., Isik A., AKSU S., ÜNER A., BÜYÜKAŞIK Y., SAYINALP N., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.32, sa.2, ss.163-167, 2015 (SCI-Expanded, Scopus, TRDizin)

115. Rebound Thrombocytosis following Induction Chemotherapy Is an Independent Predictor of a Good Prognosis in Acute Myeloid Leukemia Patients Attaining First Complete Remission

Malkan Ü. Y., Gunes G., Isik A., Eliacik E., Etgul S., Aslan T., et al.

ACTA HAEMATOLOGICA , cilt.134, sa.1, ss.32-37, 2015 (SCI-Expanded, Scopus)

116. Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case

Malkan Ü. Y., GÜNEŞ G., ELİAÇIK E., Yayar O., HAZNEDAROĞLU İ. C.

CASE REPORTS IN HEMATOLOGY , 2015 (ESCI)

117. Clinicopathological associations of acquired erythroblastopenia

GÜNEŞ G., Malkan Ü. Y., YAŞAR H. A., ELİAÇIK E., HAZNEDAROĞLU İ. C., DEMİROĞLU H., et al.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE , cilt.8, sa.12, ss.22515-22519, 2015 (SCI-Expanded, Scopus)

118. Tryptophan in Molecular Hematopoiesis

HAZNEDAROĞLU İ. C.

TRYPTOPHAN METABOLISM: IMPLICATIONS FOR BIOLOGICAL PROCESSES, HEALTH AND DISEASE , ss.253-267, 2015 (SCI-Expanded)

119. Rebound Thrombocytosis Is an Independent Predictor of Good Prognosis in AML Patients Attaining First Complete Remission

Malkan Ü. Y., GÜNEŞ G., GÖKER H., ELİAÇIK E., Isik A., SAYINALP N., et al.

BLOOD , cilt.124, sa.21, 2014 (SCI-Expanded, Scopus)

120. Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management

GÜNEŞ G., Malkan Ü. Y., AKSU S., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., et al.

BLOOD , cilt.124, sa.21, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

121. In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal gammopathy: Report of two cases

KOCABEYOĞLU S., MOCAN M. C., HAZNEDAROĞLU İ. C., ÜNER A., UZUNOSMANOĞLU E., Irkec M.

INDIAN JOURNAL OF OPHTHALMOLOGY , cilt.62, sa.9, ss.938-940, 2014 (SCI-Expanded, Scopus)

122. Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat

UZUN O., Erkan L., HAZNEDAROĞLU İ. C.

ARCHIVOS DE BRONCONEUMOLOGIA , cilt.50, sa.9, ss.407-409, 2014 (SCI-Expanded, Scopus)

123. Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells

Uz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz O., AKSU S., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.31, sa.2, ss.136-142, 2014 (SCI-Expanded, Scopus, TRDizin)

124. Next Generation Nanomedicine in the Genesis of "Ankaferd Blood Stopper Nanohemostat" A Novel Chimeric Topical Hemostatic Agent for Clinical Hemorrhages

Beyazit Y., Huri E., Purnak T., GÜLER M. Ö., HAZNEDAROĞLU İ. C.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.20, sa.4, ss.456-457, 2014 (SCI-Expanded, Scopus)

125. The Efficiency of Ankaferd Blood Stopper During the Dental Surgery in Hemorrhagic Diathesis: Case Series

AKTAŞ A., ER N., KİRİŞ S., KÖSEOĞLU O. T., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.1, ss.60-64, 2014 (SCI-Expanded, Scopus, TRDizin)

126. Clarification Letter Regarding the Gas Chromatography-Mass Spectrometry (GC-MS) Analyses of Ankaferd Hemostat, Published in UHOD 23: 171-177, 2013

HAZNEDAROĞLU İ. C., Beyazit Y., ÖZTÜRK Y., Demiralp D. O., Igci N.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.2, ss.148, 2014 (SCI-Expanded, Scopus, TRDizin)

127. Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)

HAZNEDAROĞLU İ. C.

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES , cilt.6, sa.1, 2014 (ESCI, Scopus)

128. Ibrutinib: From Molecule to Medicine

Ayyildiz O., Demirkan F., GÖKER H., HAZNEDAROĞLU İ. C., Ilhan O., KAYNAR L., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.3, ss.4-14, 2014 (SCI-Expanded, Scopus, TRDizin)

129. Acute in Vitro effects of ABS (Ankaferd Hemostat) on the Lymphoid Neoplastic Cells (B-CLL and RAJI Tumor Cell Lines)

AKALIN İ., Okur F. V., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., BÜYÜKAŞIK Y., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.4, ss.253-259, 2014 (SCI-Expanded, Scopus, TRDizin)

130. Clinical Perspectives About the Molecular Management of B-Lymphoproliferative Neoplasms

HAZNEDAROĞLU İ. C., SAYINALP N.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.3, ss.1-3, 2014 (SCI-Expanded, Scopus, TRDizin)

131. As a Rare Presentation of Waldenstrom's Macroglobulinemia; Fever

Ozen M., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.3, ss.221-222, 2014 (SCI-Expanded, Scopus, TRDizin)

132. An Immune Thrombocytopenic Purpura-Like Picture Preceding Chronic Myelomonocytic Leukemia: A Case Series and Review of the Literature

Albayrak M., ELİAÇIK E., KORUCU B., Isik A., GÜNEŞ G., AKSU S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.3, ss.213-216, 2014 (SCI-Expanded, Scopus, TRDizin)

133. Co-expression of t(5;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature

Uz B., ELİAÇIK E., Isik A., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.30, sa.4, ss.400-404, 2013 (SCI-Expanded, Scopus, TRDizin)

134. Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients

ŞAHİN F., SAYDAM G., Comert M., Uz B., Yavuz A., Turan E., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.30, sa.4, ss.351-358, 2013 (SCI-Expanded, Scopus, TRDizin)

135. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: A single center experience

GÖKER H., Ozdemir E., UZ B., BÜYÜKAŞIK Y., Turgut M., SEREFHANOGLU S., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.49, sa.3, ss.590-599, 2013 (SCI-Expanded, Scopus)

136. Evaluation of the mean platelet volume in secondary amyloidosis due to familial Mediterranean fever

Ozkayar N., Piskinpasa S., Akyel F., Dede F., YILDIRIM T., Turgut D., et al.

RHEUMATOLOGY INTERNATIONAL , cilt.33, sa.10, ss.2555-2559, 2013 (SCI-Expanded, Scopus)

137. The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia

Isik A., ELİAÇIK E., HAZNEDAROĞLU İ. C., AKSU S., SAYINALP N., BÜYÜKAŞIK Y., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.30, sa.3, ss.328-330, 2013 (SCI-Expanded, Scopus, TRDizin)

138. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate

Uz B., BÜYÜKAŞIK Y., Atay H., KELKİTLİ E., Turgut M., BEKTAŞ Ö., et al.

HEMATOLOGY , cilt.18, sa.5, ss.247-252, 2013 (SCI-Expanded, Scopus)

139. ULTRASTRUCTURAL ANALYSES OF THE NOVEL CHIMERIC HEMOSTATIC AGENT GENERATED VIA NANOTECHNOLOGY, ABS NANOHEMOSTAT, AT THE RENAL TISSUE LEVEL

Huri E., HAZNEDAROĞLU İ. C., Hayran M., Ergun M., FIRAT A., Beyazit Y., et al.

HAEMATOLOGICA , cilt.98, ss.439, 2013 (SCI-Expanded, Scopus)

140. Long-Term Sustained Hemorrhage Due to Bone Marrow Biopsy Successfully Treated With Topical Ankaferd Hemostat in a Bleeding-Prone Patient With Secondary Amyloidosis

Uz B., SAİN GÜVEN G., Isik A., KUYUMCU M. E., BEKTAŞ Ö., ELİAÇIK E., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.19, sa.3, ss.338-340, 2013 (SCI-Expanded, Scopus)

141. Circulating CD4+CD25+ Regulatory T Cells in the Pathobiology of Ulcerative Colitis and Concurrent Primary Sclerosing Cholangitis

Kekilli M., Tunc B., Beyazit Y., Kurt M., Onal I. K., Ulker A., et al.

DIGESTIVE DISEASES AND SCIENCES , cilt.58, sa.5, ss.1250-1255, 2013 (SCI-Expanded, Scopus)

142. Short-Term Effects of Ankaferd Hemostat for Renal Artery Embolization: An Experimental Study

Ozbek O., Acar K., Koc O., Saritas K., Toy H., SOLAK Y., et al.

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY , cilt.36, sa.2, ss.498-504, 2013 (SCI-Expanded, Scopus)

143. Echocardiographic Dilemma: Misleading Thrombus Appearance Due to Cavitation With Intravascular Hemolysis on a Mechanical Prosthetic Valve

Akpinar I., Sayin M. R., KARABAĞ T., Kalkan M. E., DOĞAN S. M., AYDIN M., et al.

CANADIAN JOURNAL OF CARDIOLOGY , cilt.29, sa.3, 2013 (SCI-Expanded, Scopus)

144. Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis

HAZNEDAROĞLU İ. C., Beyazit Y.

CLINICAL SCIENCE , cilt.124, ss.307-323, 2013 (SCI-Expanded, Scopus)

145. The Fourier Transform Infrared (FTIR) Spectroscopic and Mass Spectrometric Metabolomics Studies of Ankaferd Hemostat

Demiralp D. O., Igci N., Ozturk Y., Beyazit Y., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.23, sa.3, ss.171-177, 2013 (SCI-Expanded, Scopus, TRDizin)

146. Renin-Angiotensin System (RAS) Expressions in Myeloid Leukemic Cell Lines

Uz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz Ng O., BÜYÜKAŞIK Y., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.23, sa.4, ss.264-268, 2013 (SCI-Expanded, Scopus, TRDizin)

147. Generation of Chimeric "ABS Nanohemostat'' Complex and Comparing Its Histomorphological In Vivo Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model

Huri E., Beyazit Y., Mammadov R., Toksoz S., TEKİNAY A. B., GÜLER M. Ö., et al.

INTERNATIONAL JOURNAL OF BIOMATERIALS , cilt.2013, 2013 (ESCI, Scopus)

148. Bone Marrow Iron Staining is a Reliable Test for Elimination of Iron Deficiency Anemia Rather than its Diagnosis

Koca E., Cetiner D. A., BÜYÜKAŞIK Y., ÜNER A., SAYINALP N., HAZNEDAROĞLU İ. C., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.23, sa.4, ss.260-263, 2013 (SCI-Expanded, Scopus, TRDizin)

149. Oral High-Dose Ankaferd Administration Effects on Gastrointestinal System

Akbal E., KÖKLÜ S., Astarci H. M., Kocak E., Karaca G., Beyazit Y., et al.

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES , cilt.10, sa.4, ss.451-456, 2013 (SCI-Expanded, Scopus)

150. Molecular Basis of Ankaferd-Induced Hemostasis in the Management of Sternal Bleeding

Beyazit Y., Sayilir A., Suvak B., Torun S., HAZNEDAROĞLU İ. C.

HEART SURGERY FORUM , cilt.15, sa.6, 2012 (SCI-Expanded, Scopus)

151. Prohemostatic and Antithrombin Activities of Ankaferd Hemostat Are Linked to Fibrinogen Gamma Chain and Prothrombin by Functional Proteomic Analyses

Ozel-Demiralp D., Igci N., Ayhan B., Egin Y., HAZNEDAROĞLU İ. C., Akar N.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.18, sa.6, ss.604-610, 2012 (SCI-Expanded, Scopus)

152. Effects of Ankaferd hemostat on the synovial fluid of patients with osteoarthritis

ÖZTÜRK M. A., KOÇAK TUFAN Z., Demirg M. D., HAZNEDAROĞLU İ. C.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.42, sa.5, ss.768-772, 2012 (SCI-Expanded, Scopus, TRDizin)

153. Topical Ankaferd hemostat application for the management of oral cavity bleedings in children with hemorrhagic diathesis

Leblebisatan G., Bay A., Karakus S. C., Kekilli M., HAZNEDAROĞLU İ. C.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.23, sa.6, ss.494-497, 2012 (SCI-Expanded, Scopus)

154. Increased mean platelet volume (MPV) indicating the vascular risk in Alzheimer's disease (AD)

Yesil Y., Kuyumcu M. E., CANKURTARAN M., Uz B., Kara A., Kilic M. K., et al.

ARCHIVES OF GERONTOLOGY AND GERIATRICS , cilt.55, sa.2, ss.257-260, 2012 (SCI-Expanded, Scopus)

155. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat

Haznedaroglu B. Z., Beyazit Y., Walker S. L., HAZNEDAROĞLU İ. C.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.83, sa.1, ss.21-34, 2012 (SCI-Expanded, Scopus)

156. Controlling of upper gastrointestinal bleeding associated with severe immune thrombocytopenia via topical adjunctive application of Ankaferd blood stopper

Ozseker B., Shorbagi A., Efe C., HAZNEDAROĞLU İ. C., BAYRAKTAR Y.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.23, sa.5, ss.464, 2012 (SCI-Expanded, Scopus)

157. Striking Promotion of the In Vitro Myeloma Monoclonal Immunoglobulin Aggregation by Ankaferd Hemostat

Albayrak M., AKSU S., Celebi H., Albayrak A., Ginis Z., Yagci S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.1, ss.15-22, 2012 (SCI-Expanded, Scopus, TRDizin)

158. A Placebo-Controlled, Randomized, Double-Blinded, Cross-Over Phase-I Clinical Study Indicating the Safety of Topical Ankaferd Hemostat in Healthy Volunteers

Balcik O. S., Koroglu M., Cipil H., Kaftan O., Maral S., Gurel A., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.4, ss.267-274, 2012 (SCI-Expanded, Scopus, TRDizin)

159. Unusual Extramedullary Recurrence and Renal Relapse Despite Complete Chimerysm after Allografting in Ph+ ALL

Serefhanoglu S., GÖKER H., BAYDAR D., ÜNER A., ARICI M., HAZNEDAROĞLU İ. C., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.1, ss.46-50, 2012 (SCI-Expanded, Scopus, TRDizin)

160. Histopathological Alterations in the Kidney Tissue Following Topical Ankaferd Hemostat Application in a Rat Renal Injury Model

KARAKOÇ D., Akar E., AKSU S., ÜNER A., ÖZDEMİR A., HAMALOĞLU E., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.4, ss.275-281, 2012 (SCI-Expanded, Scopus, TRDizin)

161. Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in CML

AKSU S., BEKTAŞ Ö., Uz B., BÜYÜKAŞIK Y., SAYINALP N., Ozcebe O., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.1, ss.1-7, 2012 (SCI-Expanded, Scopus, TRDizin)

162. The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia

AKSU S., ŞAHİN F., Uz B., Yavuz S. A., Atay H., KELKİTLİ E., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.1, ss.8-14, 2012 (SCI-Expanded, Scopus, TRDizin)

163. The effects of Ankaferd (R) Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile

YILMAZ E., Gulec S., Torun D., HAZNEDAROĞLU İ. C., Akar N.

TURKISH JOURNAL OF HEMATOLOGY , cilt.28, sa.4, ss.276-285, 2011 (SCI-Expanded, Scopus, TRDizin)

164. Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms

Beyazit Y., Purnak T., Suvak B., Kurt M., Sayilir A., Turhan T., et al.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY , cilt.35, sa.10, ss.644-649, 2011 (SCI-Expanded, Scopus)

165. Ankaferd Blood Stopper Is More Effective Than Adrenaline Plus Lidocaine and Gelatin Foam in the Treatment of Epistaxis in Rabbits

Kelles M., Kalcioglu M. T., ŞAMDANCI E., Selimoglu E., Iraz M., MİMAN M. C., et al.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL , cilt.72, sa.5, ss.185-194, 2011 (SCI-Expanded, Scopus)

166. Ankaferd hemostat in the management of gastrointestinal hemorrhages

Beyazit Y., Kekilli M., HAZNEDAROĞLU İ. C., KAYAÇETİN E., Basaranoglu M.

WORLD JOURNAL OF GASTROENTEROLOGY , cilt.17, sa.35, ss.3962-3970, 2011 (SCI-Expanded, Scopus)

167. Surgical and histopathological effects of topical Ankaferd (R) hemostat on major arterial vessel injury related to elevated intra-arterial blood pressure

Ulus A. T., TURAN DURAL N. N., Ozyalcin S., Aydog G., Ulus F., GÖKER H., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.28, sa.3, ss.206-212, 2011 (SCI-Expanded, Scopus, TRDizin)

168. Percutaneous ankaferd injection to in vivo liver tissue in comparison to ethanol in an experimental rat model

Tas A., Koklu S., Beyazit Y., Karaca G., Astarci H. M., Akbal E., et al.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY , cilt.35, ss.549-553, 2011 (SCI-Expanded, Scopus)

169. Elevated Levels of Circulating Angiotensin Converting Enzyme in Patients with Hepatoportal Sclerosis

Beyazit Y., Ibis M., Purnak T., Turhan T., Kekilli M., Kurt M., et al.

DIGESTIVE DISEASES AND SCIENCES , cilt.56, sa.7, ss.2160-2165, 2011 (SCI-Expanded, Scopus)

170. Ankaferd hemostat for the management of tumoral GI bleeding

Beyazit Y., Kekilli M., Kurt M., Sayilir A., HAZNEDAROĞLU İ. C.

GASTROINTESTINAL ENDOSCOPY , cilt.73, sa.5, ss.1072-1073, 2011 (SCI-Expanded, Scopus)

171. Upper Gastrointestinal Bleeding in a Patient With Defective Hemostasis Successfully Treated with Ankaferd Blood Stopper

Purnak T., Ozaslan E., Beyazit Y., HAZNEDAROĞLU İ. C.

PHYTOTHERAPY RESEARCH , cilt.25, sa.2, ss.312-313, 2011 (SCI-Expanded, Scopus)

172. EVALUATION OF A HAEMOSTATIC AGENT IN RABBITS

Turhan N., Bilgili H., Captug O., Kurt M., Shorbagi A., Beyazit Y., et al.

AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES , cilt.8, sa.1, ss.61-65, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

173. THE FACTORS INFLUENCING OVERALL SURVIVAL IN NEWLY DIAGNOSED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Serefhanoglu S., BÜYÜKAŞIK Y., AKSU S., GÖKER H., SAYINALP N., Cetgner D., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , cilt.74, sa.1, ss.7-12, 2011 (ESCI, TRDizin)

174. Topical Ankaferd Bloodstopper in the Management of Critical Bleedings due to Hemorrhagic Diathesis

Turgut M., Tutkun F., Celebi N., MUĞLALI M., HAZNEDAROĞLU İ. C., GÖKER H.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.21, sa.3, ss.160-165, 2011 (SCI-Expanded, Scopus, TRDizin)

175. The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors

HAZNEDAROĞLU İ. C., Cetiner M., İLHAN O.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.21, sa.2, ss.1-3, 2011 (SCI-Expanded, Scopus, TRDizin)

176. Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia

Serefhanoglu S., BÜYÜKAŞIK Y., Emmungil H., SAYINALP N., HAZNEDAROĞLU İ. C., GÖKER H., et al.

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES , cilt.8, sa.1, ss.30-38, 2011 (SCI-Expanded, Scopus)

177. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy

SEREFHANOGLU S., BÜYÜKAŞIK Y., GÖKER H., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., et al.

LEUKEMIA RESEARCH , cilt.34, sa.12, 2010 (SCI-Expanded, Scopus)

178. Pathobiological aspects of the local bone marrow renin-angiotensin system: a review

HAZNEDAROĞLU İ. C., Beyazit Y.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM , cilt.11, sa.4, ss.205-213, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

179. Do All Hemolytic Anemias That Occur After Mitral Valve Repair Require Surgical Treatment?

Gungunes A., Akpinar I., Dogan M., Baser K., Yildirim I. S., HAZNEDAROĞLU İ. C.

CLINICAL CARDIOLOGY , cilt.33, sa.12, 2010 (SCI-Expanded, Scopus)

180. Successful treatment of endoscopic sphincterotomy-induced early hemorrhage with application of Ankaferd Blood Stopper

Beyazit Y., Koklu S., Akbal E., Kurt M., Kekilli M., HAZNEDAROĞLU İ. C.

GASTROINTESTINAL ENDOSCOPY , cilt.72, sa.6, ss.1325-1326, 2010 (SCI-Expanded, Scopus)

181. Evaluation of Hemostatic Effects of Ankaferd as an Alternative Medicine

Beyazit Y., Kurt M., Kekilli M., GÖKER H., HAZNEDAROĞLU İ. C.

ALTERNATIVE MEDICINE REVIEW , cilt.15, sa.4, ss.329-336, 2010 (SCI-Expanded, Scopus)

182. Oral Systemic Administration of Ankaferd Blood Stopper Has No Short-Term Toxicity in an In Vivo Rabbit Experimental Model

Bilgili H., Captug O., Kosar A., Kurt M., Kekilli M., Shorbagi A., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.16, sa.5, ss.533-536, 2010 (SCI-Expanded, Scopus)

183. Atraumatic Osteonecrosis After Estrogen Replacement Therapy Associated with Low Protein S Level in a Patient with Turner Syndrome

Ureten K., Ozturk M. A., Bostanci A., Ceneli O., Oezbek M., HAZNEDAROĞLU İ. C.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.16, sa.5, ss.599-601, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

184. Ankaferd Blood Stopper for Gastrointestinal Bleeding

Kurt M., Akdogan M., Ibis M., HAZNEDAROĞLU İ. C.

JOURNAL OF INVESTIGATIVE SURGERY , cilt.23, sa.4, ss.239, 2010 (SCI-Expanded, Scopus)

185. Biphasic effects of ankaferd blood stopper on renal tubular apoptosis in the rat partial nephrectomy model representing distinct levels of hemorrhage

Huri E., HAZNEDAROĞLU İ. C., Akgul T., Astarci M., Ustun H., Germiyanoulu C.

SAUDI MEDICAL JOURNAL , cilt.31, sa.8, ss.864-868, 2010 (SCI-Expanded, Scopus)

186. Ultrastructural and Morphological Analyses of the In Vitro and In Vivo Hemostatic Effects of Ankaferd Blood Stopper

Haznedaroglu B. Z., Haznedaroğlu İ. C., Walker S. L., Bilgili H., Göker H., Kosar A., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.16, sa.4, ss.446-453, 2010 (SCI-Expanded, Scopus)

187. Ankaferd Blood Stopper for controlling gastrointestinal bleeding due to distinct benign lesions refractory to conventional antihemorrhagic measures

Kurt M., Onal I. K., Akdogan M., Kekilli M., Arhan M., Sayilir A., et al.

CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY , cilt.24, sa.6, ss.380-384, 2010 (SCI-Expanded, Scopus)

188. Functional proteomic analysis of Ankaferd (R) Blood Stopper

Demiralp D. O., HAZNEDAROĞLU İ. C., Akar N.

TURKISH JOURNAL OF HEMATOLOGY , cilt.27, sa.2, ss.70-77, 2010 (SCI-Expanded, Scopus, TRDizin)

189. Prognostic Factors Affecting the Clinical Course of non-Hodgkin's Lymphomas

Beyazit Y., Kekilli M., Purnak T., GÖKER H., AKSU S., HAZNEDAROĞLU İ. C., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.20, sa.2, ss.96-102, 2010 (SCI-Expanded, Scopus, TRDizin)

190. Increased circulating soluble P-selectin in polycystic ovary syndrome

Yildiz B. O., BOZDAĞ G., HARMANCI A., Otegen U., Boynukalin K., Vural Z., et al.

FERTILITY AND STERILITY , cilt.93, sa.7, ss.2311-2315, 2010 (SCI-Expanded, Scopus)

191. Antimicrobial activity of Ankaferd Blood StopperA (R) against nosocomial bacterial pathogens

SARIBAŞ Z., ŞENER B., HAZNEDAROĞLU İ. C., Hascelik G., Kirazli S., GÖKER H.

CENTRAL EUROPEAN JOURNAL OF MEDICINE , cilt.5, sa.2, ss.198-202, 2010 (SCI-Expanded, Scopus)

192. Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: A retrospective analysis

Kurt M., Akdogan M., Onal I. K., Kekilli M., Arhan M., Shorbagi A., et al.

DIGESTIVE AND LIVER DISEASE , cilt.42, sa.3, ss.196-199, 2010 (SCI-Expanded, Scopus)

193. Safety and Efficacy of Ankaferd Blood Stopper in Dental Surgery

Ercetın S., Haznedaroğlu İ. C., Kurt M., Onal I. K., Aktaş A., Kurt O. K., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.20, sa.1, ss.1-5, 2010 (SCI-Expanded, Scopus, TRDizin)

194. The adhesion molecules of L-selectin and ICAM-1 in thrombocytosis and thrombocytopenia

Ulger Z., AKSU S., Aksoy D. Y., KÖKSAL D., HAZNEDAROĞLU İ. C., Kirazi S.

PLATELETS , cilt.21, sa.1, ss.49-52, 2010 (SCI-Expanded, Scopus)

195. DISEASE CHARACTERISTICS AND FACTORS INFLUENCING TREATMENT RESPONSE IN NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKEMIA PATIENTS: A SINGLE CENTER EXPERIENCE

Serefhanoglu S., BÜYÜKAŞIK Y., AKSU S., GÖKER H., SAYINALP N., Cetiner D., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , cilt.73, sa.3, ss.74-79, 2010 (ESCI, TRDizin)

196. Dasatinib-Induced Tumor Lysis Syndrome and Following Hematologic Remission in Fibrotic Blastic Crisis of CML

BEKTAŞ Ö., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., GÖKER H., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.20, sa.2, ss.13-16, 2010 (SCI-Expanded, Scopus, TRDizin)

197. Spinal Myeloid Sarcoma in Two Non-Leukemic Patients

Serefhanoglu S., GÖKER H., AKSU S., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ. C., et al.

INTERNAL MEDICINE , cilt.49, sa.22, ss.2493-2497, 2010 (SCI-Expanded, Scopus)

198. Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature

Serefhanoglu S., BÜYÜKAŞIK Y., GÖKER H., Akin S. C., Akin S., SAYINALP N., et al.

MEDICAL ONCOLOGY , cilt.27, sa.1, ss.55-58, 2010 (SCI-Expanded, Scopus)

199. The Gray-Zone Concept, Suboptimal Response to Imatinib, Shall be Removed from the ELN-CML Recommendations

HAZNEDAROĞLU İ. C., Koca E., AKSU S., GÖKER H., SAYINALP N., BÜYÜKAŞIK Y., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.20, sa.2, ss.25-26, 2010 (SCI-Expanded, Scopus, TRDizin)

200. Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months

SAYDAM G., HAZNEDAROĞLU İ. C., Temiz Y., Soysal T., Sucak G., TOMBULOĞLU M., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.19, sa.4, ss.195-204, 2009 (SCI-Expanded, Scopus, TRDizin)

201. Topical Ankaferd Blood Stopper Administration to Bleeding Gastrointestinal Carcinomas Decreases Tumor Vascularization

Turhan N., Kurt M., Shorbagi A., Akdogan M., HAZNEDAROĞLU İ. C.

AMERICAN JOURNAL OF GASTROENTEROLOGY , cilt.104, sa.11, ss.2874-2877, 2009 (SCI-Expanded, Scopus)

202. Changes in vascular endothelial growth factor, angiopoietins, and Tie-2 levels with G-CSF stimulation in healthy donors

Serefhanoglu S., GÖKER H., BÜYÜKAŞIK Y., Turgut M., SAYINALP N., HAZNEDAROĞLU İ. C., et al.

ANNALS OF HEMATOLOGY , cilt.88, sa.7, ss.667-671, 2009 (SCI-Expanded, Scopus)

203. Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability

Kurt M., Oztas E., KURAN S., Onal I. K., Kekilli M., HAZNEDAROĞLU İ. C.

AMERICAN JOURNAL OF EMERGENCY MEDICINE , cilt.27, sa.5, 2009 (SCI-Expanded, Scopus)

204. In Vivo Hemostatic Effect of the Medicinal Plant Extract Ankaferd Blood Stopper in Rats Pretreated With Warfarin

Cipil H. S., Kosar A., Kaya A., Uz B., HAZNEDAROĞLU İ. C., GÖKER H., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.15, sa.3, ss.270-276, 2009 (SCI-Expanded, Scopus)

205. In Vitro Anti-Bacterial Activities of Ankaferd Medicinal Plant Extract

Akkoc N., AKÇELİK M., HAZNEDAROĞLU İ. C., GÖKER H., Turgut M., AKSU S., et al.

TURKIYE KLINIKLERI TIP BILIMLERI DERGISI , cilt.29, sa.2, ss.410-415, 2009 (SCI-Expanded, Scopus)

206. The Effect of the Chernobyl Disaster on the Occurrence of Adult Acute Leukemias in Turkey

Ozatli D., GÖKER H., Buyuhasik Y., Sayinalp N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.

TURKIYE KLINIKLERI TIP BILIMLERI DERGISI , cilt.29, sa.2, ss.388-394, 2009 (SCI-Expanded, Scopus)

207. The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model

Kosar A., Cipil H. S., Kaya A., Uz B., HAZNEDAROĞLU İ. C., GÖKER H., et al.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.20, sa.3, ss.185-190, 2009 (SCI-Expanded, Scopus)

208. MOLECULAR BASIS OF THE PLEIOTROPIC EFFECTS OF ANKAFERD BLOOD STOPPER

HAZNEDAROĞLU İ. C.

IUBMB LIFE , cilt.61, sa.3, ss.290, 2009 (SCI-Expanded, Scopus)

209. Multiple Bulky Cutaneous Plasmacytomas with CNS Relapse without Bone Marrow Involvement during the Course of a Lambda Light Chain Myeloma

Serefhanoglu S., HAZNEDAROĞLU İ. C., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ.

ONKOLOGIE , cilt.32, sa.11, ss.662-664, 2009 (SCI-Expanded, Scopus)

210. Thrombomodulin and GFC levels in Legg-Calve-Perthes disease

AKSOY M. C., Aksoy D. Y., HAZNEDAROĞLU İ. C., Sayinalp N., Kirazli S., Alpaslan M.

HEMATOLOGY , cilt.13, sa.6, ss.324-328, 2008 (SCI-Expanded, Scopus)

211. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper Response

HAZNEDAROĞLU İ. C., GÖKER H.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH , cilt.36, sa.6, ss.1448-1449, 2008 (SCI-Expanded, Scopus)

212. Successful Management of Bleeding Due to Solitary Rectal Ulcer via Topical Application of Ankaferd Blood Stopper

Ibis M., Kurt M., Onal I. K., HAZNEDAROĞLU İ. C.

JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE , cilt.14, sa.9, ss.1073-1074, 2008 (SCI-Expanded, Scopus)

213. Effect of platelet count on secretion capacity: formulization and use of the formulae for evaluation of platelet secretion in thrombocytopenic patients

BÜYÜKAŞIK Y., GÖKER H., Buyukasik N. S., SAYINALP N., HAZNEDAROĞLU İ. C., Ozcebea O. I.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.19, sa.7, ss.633-637, 2008 (SCI-Expanded, Scopus)

214. Extramedullary plasmacytomas of the thyroid and pericardium as initial presentation of multiple myeloma

Serefhanoglu S., SAYINALP N., HAZNEDAROĞLU İ. C., GÖKER H., Cetiner D., AKSU S., et al.

ANNALS OF HEMATOLOGY , cilt.87, sa.10, ss.853-854, 2008 (SCI-Expanded, Scopus)

215. Endoscopic application of Ankaferd blood stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: A case report

Kurt M., Disibeyaz S., Akdogan M., Sasmaz N., AKSU S., HAZNEDAROĞLU İ. C.

AMERICAN JOURNAL OF GASTROENTEROLOGY , cilt.103, sa.8, ss.2156-2158, 2008 (SCI-Expanded, Scopus)

216. Severe arterial thrombophilia associated with a homozygous MTHFR gene mutation (A1298C) in a young man with Klinefelter syndrome

Ozbek M., Ozturk M. A., Ureten K., Ceneli O., ERDOĞAN M., HAZNEDAROĞLU İ. C.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.14, sa.3, ss.369-371, 2008 (SCI-Expanded, Scopus)

217. Evidence for higher red blood cell mass in persons with unconjugated Hyperbilirubinemia and Gilbert's syndrome

BÜYÜKAŞIK Y., Akman U., Buyukasik N. S., GÖKER H., Kilicarslan A., Shorbagi A. I., et al.

AMERICAN JOURNAL OF THE MEDICAL SCIENCES , cilt.335, sa.2, ss.115-119, 2008 (SCI-Expanded, Scopus)

218. Soluble platelet glycoprotein V in distinct disease states of pathological thrombopoiesis

Acar K., AKSU S., Beyazit Y., HAZNEDAROĞLU İ. C., Koca E., Cetiner D., et al.

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION , cilt.100, sa.1, ss.86-90, 2008 (SCI-Expanded, Scopus)

219. Change in Blood Coagulation Parameters After Total Body Irradiation

CENGİZ M., GOEKER H., Yazici G., ZORLU F., BUEYUEKASIK Y., KIRAZLI S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.18, sa.3, ss.135-140, 2008 (SCI-Expanded, Scopus, TRDizin)

220. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis

HALİL M. G., Cankurtaran M., DOĞU B. B., Ulger Z., Piskinpasa S., Gedik A., et al.

ANNALS OF PHARMACOTHERAPY , cilt.41, sa.1, ss.41-45, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

221. The search for a common thrombophilic state during the active state of inflammatory bowel disease

Yurekli B. P. S., Aksoy D. Y., Aybar M., Egesel T., Gurgey A., Hascelik G., et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.40, sa.9, ss.809-813, 2006 (SCI-Expanded, Scopus)

222. Lack of association between familial Mediterranean fever and angiotensin converting enzyme gene polymorphism

Calguneri O., Ozturk M., Kiraz S., Ertenli I., Onat A., Ureten K., et al.

JOINT BONE SPINE , cilt.73, sa.3, ss.334-336, 2006 (SCI-Expanded, Scopus)

223. Changing clinical manifestations of a T-peripheral lymphoma: From hypereosinophilic syndrome to questionable Kimura's disease resulting in parotid mass

Beyazit Y., Haznedaroglu I., Aksu S., Kekilli M., ÜNER A., Agbaht K., et al.

LEUKEMIA & LYMPHOMA , cilt.47, sa.2, ss.357-360, 2006 (SCI-Expanded, Scopus)

224. Rethinking leptin and insulin action: Therapeutic opportunities for diabetes

Yildiz B., Haznedaroglu I.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY , cilt.38, ss.820-830, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

225. Myocardial infarction and deep venous thrombosis in a young patient with Behcet disease

Calguneri M., Aydemir K., Ozturk M., Haznedaroglu I., Kiraz S., Ertenli I.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.12, sa.1, ss.105-109, 2006 (SCI-Expanded, Scopus)

226. Overt gastrointestinal bleeding in haematologic neoplasms

Soylu A., Buyukasik Y., Cetiner D., Buyukasik N., Koca E., Haznedaroglu I., et al.

DIGESTIVE AND LIVER DISEASE , cilt.37, sa.12, ss.917-922, 2005 (SCI-Expanded, Scopus)

227. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation

Koca E., Cetiner D., Goker H., Aksu S., Ozcebe O., Haznedaroglu I., et al.

CLINICAL NEPHROLOGY , cilt.64, sa.4, ss.324-326, 2005 (SCI-Expanded, Scopus)

228. Increased soluble glycoprotein V concentration during the acute onset of unstable angina pectoris in association with chronic cigarette smoking

Atalar E., Haznedaroglu I., Kilic H., Ozer N., Coskun S., Ozturk E., et al.

PLATELETS , cilt.16, sa.6, ss.329-333, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

229. Enhanced tissue factor pathway inhibitor response as a defense mechanism against ongoing local microvascular events of Legg-Calve-Perthes disease

Cemalettin M., Aksoy D., Haznedaroglu I., Sayinalp N., Kirazli S., Alpaslan M.

PEDIATRIC HEMATOLOGY AND ONCOLOGY , cilt.22, sa.5, ss.391-399, 2005 (SCI-Expanded, Scopus)

230. No alteration in the PFA-100 in vitro bleeding time induced by the Ginkgo biloba special extract, EGb 761, in elderly patients with mild cognitive impairment

Halil M. G., CANKURTARAN M., YAVUZ B., OZKAYAR N., ULGER Z., DEDE D., et al.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.16, sa.5, ss.349-353, 2005 (SCI-Expanded, Scopus)

231. Immediate effects of fluvastain on circulating soluble endothelial protein C and free tissue factor pathway inhibitor in acute coronary syndromes

Atalar E., Coskun S., Haznedaroglu I., Yucel N., Ozer N., Sivri B., et al.

CARDIOVASCULAR DRUGS AND THERAPY , cilt.19, sa.3, ss.177-181, 2005 (SCI-Expanded, Scopus)

232. Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia

GÖNEN C., Haznedaroglu I., Aksu S., Koca E., Goker H., Buyukasik Y., et al.

PLATELETS , cilt.16, sa.1, ss.31-37, 2005 (SCI-Expanded, Scopus)

233. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?

Erman M., Abali H., ORAN B., Haznedaroglu I., Canpinar H., KİRAZLI Ş., et al.

ANNALS OF ONCOLOGY , cilt.15, sa.11, ss.1622-1626, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

234. Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level

Cobankara V., Ozath D., Kiraz S., ÖZTÜRK A., Ertenli I., Turk T., et al.

CLINICAL RHEUMATOLOGY , cilt.23, sa.5, ss.430-434, 2004 (SCI-Expanded, Scopus)

235. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders

Sayinalp N., Cinar H., ÜNER A., Haznedaroglu I., Buyukasik Y., Goker H., et al.

CLINICAL AND LABORATORY HAEMATOLOGY , cilt.26, sa.4, ss.265-268, 2004 (SCI-Expanded, Scopus)

236. Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia

Dizdar O., Yurekli B., Purnak T., Aksu S., Haznedaroglu I.

ANNALS OF PHARMACOTHERAPY , cilt.38, ss.1319-1320, 2004 (SCI-Expanded, Scopus)

237. The predictability of factor V Leiden (FV : Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance

Sayinalp N., Haznedaroglu I., Aksu S., Buyukasik Y., Goker H., Parlak H., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.10, sa.3, ss.265-270, 2004 (SCI-Expanded, Scopus)

238. Angiotensin-converting enzyme gene polymorphism in Behcet's disease

Ozturk M., Calguneri M., Kiraz S., Ertenli I., Onat A., Ureten K., et al.

CLINICAL RHEUMATOLOGY , cilt.23, sa.2, ss.142-146, 2004 (SCI-Expanded, Scopus)

239. Current debates in antiphospholipid syndrome: The acquired antibody-mediated thrombophilia

Ozturk M., Haznedaroglu I., Turgut M., Goker H.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.10, sa.2, ss.89-126, 2004 (SCI-Expanded, Scopus)

240. Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behcet's disease

Ozturk M., Ertenli I., Kiraz S., Haznedaroglu I., Celik I., Kirazli S., et al.

RHEUMATOLOGY INTERNATIONAL , cilt.24, sa.2, ss.98-102, 2004 (SCI-Expanded, Scopus)

241. How hematopoietic stem cells know and act in cardiac microenvironment for stem cell plasticity? Impact of local renin-angiotensin systems

Ozturk M., Guven G., Haznedaroglu I.

MEDICAL HYPOTHESES , cilt.63, sa.5, ss.866-874, 2004 (SCI-Expanded, Scopus)

242. Protein C inhibitor and serum amyloid A in immune thrombocytopaenic purpura

Sayinalp N., Haznedaroglu I., Buyukasik Y., Goker H., Aksu S., Kocoglu H., et al.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH , cilt.32, sa.1, ss.62-65, 2004 (SCI-Expanded, Scopus)

243. Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia

Atalar E., Haznedaroglu I., Acil T., Ozer N., Kilic H., Ovunc K., et al.

PLATELETS , cilt.14, ss.407-411, 2003 (SCI-Expanded, Scopus)

244. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis

Apras S., Ertenli I., Ozbalkan Z., Kiraz S., Ozturk M., Haznedaroglu I., et al.

ARTHRITIS AND RHEUMATISM , cilt.48, sa.8, ss.2256-2261, 2003 (SCI-Expanded, Scopus)

245. Decreased protein Z concentrations complicating the hypercoagulable state of Behcet's disease

Ozturk M., Ozbalkan Z., Onat A., Ertenli I., Kiraz S., Aytemir K., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.9, sa.3, ss.259-263, 2003 (SCI-Expanded, Scopus)

246. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system

Haznedaroglu I., Ozturk M.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY , cilt.35, sa.6, ss.867-880, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

247. Pathologic thrombopoiesis of rheumatoid arthritis

Ertenli I., Kiraz S., Ozturk M., Haznedaroglu I., Celik I., Calguneri M.

RHEUMATOLOGY INTERNATIONAL , cilt.23, sa.2, ss.49-60, 2003 (SCI-Expanded, Scopus)

248. Increased soluble FAS suggests delayed apoptosis in familial Mediterranean fever complicated with amyloidosis

Kiraz S., Ertenli I., Ozturk M., Haznedaroglu I., Calguneri M., Atalar E., et al.

JOURNAL OF RHEUMATOLOGY , cilt.30, sa.2, ss.313-315, 2003 (SCI-Expanded, Scopus)

249. Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension

Haznedaroglu I., Atalar E., Ozturk M., Ozer N., Ovunc K., Aksoyek S., et al.

PLATELETS , cilt.13, sa.7, ss.395-399, 2002 (SCI-Expanded, Scopus)

250. Bloodstream thrombopoietin in rheumatoid arthritis with thrombocytosis

Kiraz S., Ertenli I., Ozturk M., Haznedaroglu I., Celik I., Kirazli S., et al.

CLINICAL RHEUMATOLOGY , cilt.21, sa.6, ss.453-456, 2002 (SCI-Expanded, Scopus)

251. Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

Abali H., Gullu İ. H., Engin H., Haznedaroglu I., Erman M., Tekuzman G.

MEDICAL HYPOTHESES , cilt.59, sa.3, ss.344-348, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

252. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state

Yildiz B., Haznedaroglu I., Kirazli S., Bayraktar M.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM , cilt.87, sa.8, ss.3871-3875, 2002 (SCI-Expanded, Scopus)

253. Thrombopoietin as a drug: Biologic expectations, clinical realities, and future directions

Haznedaroglu I., Goker H., Turgut M., Buyukasik Y., Benekli M.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.8, sa.3, ss.193-212, 2002 (SCI-Expanded, Scopus)

254. Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease

Buyukasik Y., Karakus S., Goker H., Haznedaroglu I., Ozatli D., Sayinalp N., et al.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.13, sa.4, ss.349-353, 2002 (SCI-Expanded, Scopus)

255. Hemostatic parameters in Behcet's disease: a reappraisal

Kosar A., Ozturk M., Haznedaroglu I., Karaaslan Y.

RHEUMATOLOGY INTERNATIONAL , cilt.22, sa.1, ss.9-15, 2002 (SCI-Expanded, Scopus)

256. Proinflammatory and hematopoietic cytokines in reactive and clonal thrombycytosis

Ozturk M., Kiraz S., Ertenli I., Calguneri M., Haznedaroglu I.

SOUTHERN MEDICAL JOURNAL , cilt.95, sa.5, ss.565-566, 2002 (SCI-Expanded, Scopus)

257. Piebaldism associated with congenital dyserythropoietic anemia type II (HEMPAS)

Koklu S., Ertugrul D., Onat A., Karakus S., Haznedaroglu I., Buyukasik Y., et al.

AMERICAN JOURNAL OF HEMATOLOGY , cilt.69, sa.3, ss.210-213, 2002 (SCI-Expanded, Scopus)

258. Plasma thrombospondin in immune thrombocytopenic purpura

Ozcebe O., Karakus S., Haznedaroglu I., Goker H., Kosar A., Kocoglu H., et al.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH , cilt.30, sa.1, ss.52-55, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

259. Effects of extracorporeal circulation on thrombin-antithrombin III and prothrombin fragment 1+2 levels

Yilmaz M., Haznedaroglu I., Kirazli S., Pasaoglu I.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.8, sa.1, ss.61-63, 2002 (SCI-Expanded, Scopus)

260. Pathological haemostasis and 'prothrombotic state' in Behcet's disease

Kiraz S., Ertenli I., Ozturk M., Haznedaroglu I., Celik I., Calguneri M.

THROMBOSIS RESEARCH , cilt.105, sa.2, ss.125-133, 2002 (SCI-Expanded, Scopus)

261. Plasma thrombopoietin in patients with cavernous transformation of the portal vein

Goker H., Egesel T., Karakus S., Haznedaroglu I., Apras S., Buyukasik Y., et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY , cilt.75, sa.1, ss.91-94, 2002 (SCI-Expanded, Scopus)

262. Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behcet's disease: evidence of a prethrombotic state

Ozatli D., Sayinalp N., Buyukasik Y., Karakus S., Haznedaroglu I., Kirazli S., et al.

RHEUMATOLOGY INTERNATIONAL , cilt.21, sa.4, ss.137-140, 2002 (SCI-Expanded, Scopus)

263. Hyperhomocysteinaemia and activated protein C resistance in Behcet's disease

Altinbas A., Aytemur K., Tokgozoglu L., Ozturk M., Kosar A., Haznedaroglu I., et al.

JOURNAL OF INTERNAL MEDICINE , cilt.248, sa.3, ss.267-268, 2000 (SCI-Expanded, Scopus)

264. The plasma levels of prostanoids and plasminogen activator inhibitor-1 in primary and secondary thrombocytosis

Birdane A., Haznedaroglu I., Ozath D., Sayinalp N., Kosar A., Buyukasik Y., et al.

EXPERIMENTAL HEMATOLOGY , cilt.28, sa.7, ss.120, 2000 (SCI-Expanded, Scopus)

265. Behcet's disease.

Haznedaroglu I., Ozcebe O., Dundar S.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.342, sa.8, ss.588, 2000 (SCI-Expanded, Scopus)

266. Aplastic pancytopenia associated with thymoma [2]

Coplu L., Selcuk Z., Haznedaroglu I., Dogan R., Gungen Y.

Annals of Hematology , cilt.79, sa.11, ss.648-650, 2000 (SCI-Expanded, Scopus)

267. A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway

Haznedaroglu I., Arici M., Buyukasik Y.

MEDICAL HYPOTHESES , cilt.54, sa.1, ss.80-83, 2000 (SCI-Expanded, Scopus)

268. Serum L-selectin and P-selectin levels in lymphomas

Haznedaroglu I., Benekli M., Ozcebe O., Savas M., Gullu IH G. I., Dundar S., et al.

HAEMATOLOGIA , cilt.30, sa.1, ss.27-30, 2000 (SCI-Expanded)

269. Selectin adhesion molecules in Behcet's disease

Haznedaroglu S., Karaaslan Y., Buyukasik Y., Kosar A., Ozcebe O., Haznedaroglu I., et al.

ANNALS OF THE RHEUMATIC DISEASES , cilt.59, sa.1, ss.61-63, 2000 (SCI-Expanded, Scopus)

270. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever

KİRAZ S., ERTENLİ A. İ., ARICI M., Calguneri M., HAZNEDAROĞLU İ. C., ÇELİK İ., et al.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.16, sa.6, ss.721-724, 1998 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 66

1. Determination of Drug Sensitivity Subgroups in Acute Myeloblastic Leukemia by the Detection of Gene Based Cancer Biomarkers and the Prediction of Prognosis and Treatment.

TÜRK TÜRK S., TÜRK C., HAZNEDAROĞLU İ. C., SAYINALP N.

The Febs Congress, 6 - 11 Temmuz 2019 Sürdürülebilir Kalkınma

2. Proteomic Investigation of In-Vitro Antineoplastic Effect of Ankaferd Hemostat with 2D Gel Electrophoresis and MALDI-TOF/TOF-MS in HepG2, Caco-2 and HT-29 Cancer Cells

NENNİ M., ÇELEBİER M., SÜSLÜ İ., HAZNEDAROĞLU İ. C.

The International Society on Thrombosis and Hemostasis (ISTH), 6 - 10 Temmuz 2019, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

3. Proteomic Investigation of Ankaferd Hemostat Application on MCF-7 Breast Cancer Cell Line

ZEKİ Ö. C., NENNİ M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., HAZNEDAROĞLU İ. C.

International Multidisciplinary Symposium on Drug Research and Development (DRD), 1 - 03 Temmuz 2019, (Özet Bildiri) Sürdürülebilir Kalkınma

4. THE EVALUATION OF THE CLINICOPATHOLOGIC CHARACTERISTICS OF T-CELL NON-HODGKIN’S LYMPHOMA: THE SINGLE CENTER EXPERIENCE

SAYINALP N., ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., AKSU S., DEMİROĞLU H., et al.

15th International Conference on Malignant Lymphoma, İsviçre, 18 - 22 Haziran 2019, cilt.37, ss.366, (Özet Bildiri)

5. ASEMPTOMATİK D-DİMER YÜKSEKLİĞİ İMMÜNMONULATUAR KULLANAN MULTİPLE MYELOMADA TROMBOZU TAHMİN EDER Mİ: GERÇEK YAŞAM VERİSİ

AYDIN M. S., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., YAZGAN S. Ç., DEMİROĞLU H., ÖZCEBE O. İ., et al.

4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Nisan 2019, (Özet Bildiri)

6. ALLOJENİK KÖK HÜCRE NAKLİ SONRASI RELAPS İZLENEN AKUT LÖSEMİ HASTALARINDA TEDAVİ SEÇENEKLERİ: DONÖR LENFOSİT İNFUZYONU VE İKİNCİ ALLOJENİK KÖK HÜCRE NAKLİNİN KARŞILAŞTIRILMASI

ALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., OKAY M., ÇİFTÇİLER R., SAYINALP N., et al.

4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Nisan 2019, (Özet Bildiri)

7. MULTİPLE MYELOM HASTALARINDA İNDUKSİYON TEDAVİ SÜRESİNİN SAĞKALIMA ETKİSİ

ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., et al.

3. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Türkiye, 8 - 09 Mart 2019, (Özet Bildiri)

8. Long-Term Results of Non-Fludarabine Versus Fludarabine-Based Conditioning Regimens in Severe Aplastic Anemia Patients

ALADAĞ KARAKULAK E., DEMİROĞLU H., Ciftciler R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

9. DASATİNİB KULLANIRKEN PLEVRAL EFFÜZYONU GELİŞİP, KÜÇÜK HÜCRELİ AKCİĞER KANSERİ TANISI ALAN BİR OLGU

ÇİFTÇİLER R., ALADAĞ KARAKULAK E., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., AKSU S., et al.

44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.364-365, (Özet Bildiri) Sürdürülebilir Kalkınma

10. MRG’DE TESADÜFEN SAPTANAN KEMİK İLİĞİNİN DİFFÜZ SİNYAL DEĞİŞİKLİKLERİ LENFOHEMATOPOETİK HASTALIKLARI ÖNGÖREBİLİR Mİ?

ÇİFTÇİLER R., ALADAĞ KARAKULAK E., AKSU S., SAYINALP N., DEMİROĞLU H., GÖKER H., et al.

44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.266, (Özet Bildiri)

11. LENALIDOMID İLE MYELOMDA OTOLOG NAKİL SONRASI İLK NÜKSDE TALİDOMİD VE BORTEZOMİBE KIYASLA DAHA İYİ İLERLEMESİZ SAĞKALIM

DEMİROĞLU H., AKSU S., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., et al.

TÜRK HEMATOLOJİ DERNEĞİ, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)

12. LENALİDOMİD İLE MYELOMDA OTOLOG NAKİL SONRASI İLK NÜKSDE TALİDOMİD VE BORTEZOMİB’E KIYASLA DAHA İYİ İLERLEMESİZ SAĞKALIM

MALKAN Ü. Y., BÜYÜKAŞIK Y., DEMİROĞLU H., ÇİFTÇİLER R., GÜNEŞ G., OKAY M., et al.

44.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.191-192, (Özet Bildiri)

13. AĞIR APLASTİK ANEMİ HASTALARINDA HEMATOPOETİK KÖK HÜCRE NAKLİNDE KULLANILAN HAZIRLIK REJİMLERİNİN KARŞILAŞTIRILMASI

ALADAĞ KARAKULAK E., DEMİROĞLU H., ÇİFTÇİLER R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., et al.

44.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.261, (Özet Bildiri)

14. PRİMER VE EDİNSEL İMMÜN YETMEZLİĞİ OLAN HASTALARDA MALİGNİTE SIKLIĞI

ÇİFTÇİLER R., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C., SAYINALP N.

44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.276-277, (Özet Bildiri)

15. T HÜCRELİ LENFOMA HASTALARININ KLİNİK ÖZELLİKLERİNİN DEĞERLENDİRİLMESİ: TANIDAN PROGNOZA TEK MERKEZ DENEYİMİ

DEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.

TÜRK HEMATOLOJİ DERNEĞİ, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)

16. Retrospective and multicenter analysis of efficacy and safety of ruxolitinib in 176 Turkish patient with myelofibrosis: updated data

SOYER N., ALİ R., TURGUT M., HAZNEDAROĞLU İ. C., YILMAZ A. F., AYDOĞDU İ., et al.

9. International Eurasian Hematology Oncology Congress, 17 - 20 Ekim 2018, (Özet Bildiri)

17. BRENTIXUMAB VEDOTIN IN CD30 LYMPHOMAS: SINGLE CENTER EXPERIENCE

DEMİROĞLU H., SAYINALP N., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., GÖKER H., et al.

IX. INTERNATIONAL EHOC, 17 - 20 Ekim 2018, cilt.73, (Tam Metin Bildiri)

18. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma

OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., CIFTCILER R., Aladag E., et al.

9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Türkiye, 17 - 20 Ekim 2018, cilt.73, (Özet Bildiri)

19. Descriptive analysis of myeloproliferative diseases and its complications

OKAY M., MALKAN Ü. Y., BÖLEK E. Ç., Aladag E., HAZIYEV T., SAYINALP N., et al.

9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Türkiye, 17 - 20 Ekim 2018, cilt.73, (Özet Bildiri)

20. RELAPS/REFRAKTER LENFOMADA OTOLOG KÖK HÜCRE TRANSPLANTASYONUNDA MİTOKSANNTRON-MELFALAN HAZIRLAMA REJİMİ

OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., malkan Ü. Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., et al.

6. HEMATOLOJİK ONKOLOJİ KONGRESİ, Türkiye, 18 - 22 Eylül 2018, (Tam Metin Bildiri)

21. RELAPS/REFRAKTER LENFOMADA OTOLOG KÖK HÜCRE TRANSPLANTASYONUNDA MİTOKSANTRON-MELFALAN HAZIRLAMA REJİMİ

OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., et al.

5. HEMATOLOJİK ONKOLOJİ KONGRESİ, Kıbrıs (Kktc), 20 - 22 Eylül 2018, (Özet Bildiri)

22. AKUT MYELOİD LÖSEMİLİ BİR OLGULDA SİTOZİN ARABİNOZİD İLİŞKİLİ PULMONER TOKSİSİTE

ÇİFTÇİLER R., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C., AKSU S., DEMİROĞLU H., GÖKER H., et al.

4.İLAÇ VE TEDAVİ KONGRESİ, Kıbrıs (Kktc), 19 - 23 Eylül 2018, ss.254, (Özet Bildiri)

23. EFFECT OF THE INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTS

ALADAĞ KARAKULAK E., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., et al.

The International Congress of BMT 2018, Busan, Güney Kore, 30 Ağustos - 01 Eylül 2018, (Özet Bildiri)

24. Investigation of The Effect of Commercial Herbal Mixture on HepG2 Liver Cancer Cell Line by Proteomic Approach

NENNİ M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., ÇELEBİER M., HAZNEDAROĞLU İ. C.

12th International Symposium on Pharmaceutical Sciences, 26 - 29 Haziran 2018, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

25. DOES ASYMPTOMATIC D-DIMER ELEVATION PREDICT THROMBOSIS IN PATIENTS ON IMMUNOMODULATORY DRUGS IN MULTIPLE MYELOMA: REAL-LIFE DATA

AYDIN M. S., YAZGAN S. Ç., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., KELKİTLİ E., TURGUT M., et al.

23rd Congress of EHA, Stockholm, İsveç, 14 - 17 Haziran 2018, (Özet Bildiri)

26. Does Asymptomatic D-Dimer Elevation Predict Thrombosis in Patient on Immunomodulatory Drugs in Multiple Myeloma: Real-Life Data

AYDIN M. S., YAZGAN S. C., ALADAĞ KARAKULAK E., Çiftçiler R., KELKİTLİ E., TURGUT M., et al.

European Hemtology Association, 14 - 17 Haziran 2018, (Özet Bildiri)

27. PLAZMA HÜCRELİ LÖSEMİ ŞEKLİNDE PREZENTE OLAN WALDENSTROM MAKROGOBULİNEMİSİ

ÇİFTÇİLER R., OKAY M., ALADAĞ KARAKULAK E., HEZİYEV T., AKSU S., SAYINALP N., et al.

2. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Mayıs 2018, (Özet Bildiri)

28. Common medical problems in adult patients with Hemophilia A: A single center experience

AYDIN M. S., OKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., DEMİROĞLU H., GÖKER H., et al.

15. INTERNATIONAL HEMOPHILIA CONGRESS OF TURKEY, İstanbul, Türkiye, 4 - 07 Nisan 2018, (Özet Bildiri)

29. Echocardiographic Evaluation of Patients with Hodgkin and Non Hodgkin Lymphoma before and after Hematopoietic Stem Cell Transplantation

KELKİTLİ E., BÜYÜKAŞIK Y., DEMİROĞLU H., ŞAHİNER M. L., OKAY M., AYDIN M. S., et al.

59th ASH, 9 - 12 Aralık 2017, cilt.130, ss.5521, (Özet Bildiri)

30. Prognosis of Multiple Myeloma in Younger Patients Who Are Undergoing Upfront Autologuous Stem Cell Transplantation

KELKİTLİ E., GÖKER H., DEMİROĞLU H., TURGUT M., OKAY M., SAYINALP N., et al.

LYMPHOMA AND MYELOMA 2017, New York, Amerika Birleşik Devletleri, 26 - 28 Kasım 2017, cilt.1, ss.43-44, (Özet Bildiri)

31. Donor Lymphocyte Infusions: Single Center Experience

KELKİTLİ E., GÖKER H., TURGUT M., DEMİROĞLU H., SAYINALP N., AKSU S., et al.

LYMPHOMAMYELOMA 2017, New York, Amerika Birleşik Devletleri, 26 - 28 Kasım 2017, cilt.1, ss.48, (Özet Bildiri)

32. Epidemiological Estimatesand Treatment Practice Pattern in Polycytemia Vera Patients in Turkey:Results Based on an Expert Panel

BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., ÖZET G., Ar C., Özcan M., Güvenç B., et al.

ISPOR 20th Annual European Congress, 4 - 08 Kasım 2017, (Özet Bildiri)

33. The Modelled Effetiveness oh Ruxolitinib on survival in PV Patients with Hydroxyurea Resistance /Intolerancein Turkey

BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., ÖZET G., Ar C., Özcan M., Güvenç B., et al.

ISPOR 20th Annual Eurepean Congress, 4 - 08 Kasım 2017, (Özet Bildiri)

34. kronik myeloproliferatif neoplazili hastalarda ruksolitinib etkinlik ve güvenliği: çok merkezli ve geriye dönük çalışma

SOYER N., TURGUT M., HAZNEDAROĞLU İ. C., YILMAZ A. F., AYDOĞDU İ., PİR A., et al.

43.ulusal hematoloji kongresi, Türkiye, 1 - 04 Kasım 2017, (Özet Bildiri)

35. KRONİK MYELOPROLİFERATİF NEOPLAZİLİ HASTALARDA RUKSOLİTİNİB ETKİNLİK VE GÜVENLİĞİ: ÇOK MERKEZLİ VE GERİYE DÖNÜK ÇALIŞMA.

SOYER N., TURGUT M., HAZNEDAROĞLU İ. C., YILMAZ A. F., AYDOĞDU İ., PİR A., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017, (Özet Bildiri)

36. Prognosis of Multiple Myeloma in Younger Patients who Undergoing Upfront Autologous Stem Cell Transplantation

KELKİTLİ E., GÖKER H., demiroglu H., TURGUT M., SAYINALP N., AKSU S., et al.

LYMPHOMA MYELOMA 2017, 26 - 28 Ekim 2017, (Özet Bildiri)

37. Donor Lymhocyte Infusion: Single Center Experience

KELKİTLİ E., GÖKER H., TURGUT M., Demiroğlu H., SAYINALP N., AKSU S., et al.

LYMHOMA MYELOMA 2017, 26 - 28 Ekim 2017, (Özet Bildiri)

38. Efficacy and safety of Ruxolitinib in Turkish Patients with chronic myeloproliferatif neoplasms:A multicenter and retrospective analysis

SOYER N., TURGUT M., HAZNEDAROĞLU İ. C., yılmaz f., AYDOĞDU İ., PİR A., et al.

AHOS, 21 - 24 Eylül 2017, (Özet Bildiri)

39. Efficiacy and safety of ruxolitinib in Turkish patients with chronic myeloprolipherative neoplasms:A multicenter and retropective analysis

SOYER N., TURGUT M., HAZNEDAROĞLU İ. C., YILMAZ F., AYDOĞDU İ., PİR A., et al.

4th Aegean Hematology Oncology Symposium, 21 - 24 Eylül 2017, (Tam Metin Bildiri)

40. EFFECT OF INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTS

DEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., et al.

INTERNATIONAL CONGRESS OF BMT 2018, Busan, Güney Kore, 30 Ağustos - 01 Eylül 2018, cilt.53, (Tam Metin Bildiri)

41. Amyloidosis Induced Abnormal coagulopathy associated with multible coagulation Factor Deficiencies.

malkan Ü. Y., DEMİROĞLU H., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N.

XXVI. Congress of the international society on Thrombosis and Haemostasis, Berlin, Almanya, 08 Temmuz 2017 - 13 Ocak 2018, cilt.1, ss.402, (Özet Bildiri)

42. The Impact of Chemo/Immune Therapy-‐Related Cytopeniason the Clinical Course of Chronic Lymphoid Leukemia

OKAY M., HAZNEDAROĞLU İ. C., malkan Ü. Y., GÜNEŞ G., aslan n., AKSU S., et al.

iwcll2017, New York, Amerika Birleşik Devletleri, 12 - 15 Mayıs 2017, (Özet Bildiri)

43. Kemoterapiye refrakter primer mediastinal granülositik sarkom hastasının allojeneik kök hücre transplantasyonu ile tedavisi

ETGÜL S., MALKAN Ü. Y., TURGUT M., DEMİROĞLU H., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., et al.

2. Hematolojik Onkoloji Kongresi, Kıbrıs (Kktc), 16 - 19 Şubat 2017, (Özet Bildiri)

44. Determination of chemoterapoetic drug sensitivity subgroups of acute leukemia

TÜRK S., GHASEMİ M., MALKAN Ü. Y., ERİKÇİ A., GÖKER H., SAYINALP N., et al.

41. FEBS Kongresi, Türkiye, 3 - 08 Eylül 2016, (Özet Bildiri)

45. Determination of chemoterapoetic drug sensitivity subgroups of acute leukemia

TÜRK S., Ghasemi M., MALKAN Ü. Y., Erikci A., GÖKER H., SAYINALP N., et al.

41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Türkiye, 3 - 08 Eylül 2016, cilt.283, ss.373-374, (Özet Bildiri)

46. Determination of chemoterapoetic drugsensitivity subgroups of acute leukemia

Türk S., Ghasemi M., malkan Ü. Y., ERİKÇİ A., GÖKER H., HAZNEDAROĞLU İ. C., et al.

The FEBS Journal, 3 - 08 Eylül 2016, (Özet Bildiri)